Advances in non-biological drugs for the treatment of rheumatoid arthritis

References

• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001. doi: 10.1038/nrdp.2018.1
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American college of rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182–8.
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Kalpourtzi N, Alamanos Y, et al. EMENO study group. Prevalence of rheumatoid arthritis in Greece: results from the national health examination survey EMENO. Rheumatol Int. 2023;43(7):1349–1355. doi: 10.1007/s00296-023-05316-3
   PubMed Web of Science ®Google Scholar
• Venetsanopoulou AI, Alamanos Y, Skalkou A, et al. The changing incidence of rheumatoid arthritis over time in north-west Greece: data from a referral centre. Scand J Rheumatol. 2023;52(4):327–334. 10.1080/03009742.2022.2058178
   PubMed Web of Science ®Google Scholar
• Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM. 2010;103(3):139–46. doi: 10.1093/qjmed/hcp165
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320(13):1360–1372. doi: 10.1001/jama.2018.13103
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–2581. doi: 10.1002/art.27584
   PubMed Web of Science ®Google Scholar
• Cush JJ. Rheumatoid arthritis: early diagnosis and treatment. Med Clin North Am. 2021;105(2):355–365. doi: 10.1016/j.mcna.2020.10.006
   PubMed Web of Science ®Google Scholar
• Vliet Vlieland TP, van den Ende CH. Nonpharmacological treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2011;23(3):259–64. doi: 10.1097/BOR.0b013e32834540fb
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15. doi: 10.1136/annrheumdis-2015-207524
   PubMed Web of Science ®Google Scholar
• Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):744–759. doi: 10.1136/annrheumdis-2019-216656
   PubMed Web of Science ®Google Scholar
• Hazlewood GS, Whittle SL, Kamso MM, et al. Disease‐modifying anti‐rheumatic drugs for rheumatoid arthritis: a systematic review and network meta‐analysis. Cochrane Database Syst Rev. 2020;2020:CD013562. doi: 10.1002/14651858.CD013562
   Google Scholar
• Venetsanopoulou AI, Alamanos Y, Voulgari PV, et al. Epidemiology of rheumatoid arthritis: genetic and environmental influences. Expert Rev Clin Immunol. 2022;18:923–931. doi: 10.1080/1744666X.2022.2106970
   PubMed Web of Science ®Google Scholar
• Alivernini S, Firestein GS, McInnes IB The pathogenesis of rheumatoid arthritis. Immunity. 2022;55:2255–2270.
   Google Scholar
• Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. doi: 10.1136/ard-2022-223356
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924–939.
   PubMed Web of Science ®Google Scholar
• Crofford LJ Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15 Suppl 3(Suppl 3):S2.10.1186/ar4174
   PubMedGoogle Scholar
• Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum. 2010;39:294–312. doi: 10.1016/j.semarthrit.2008.08.001
   PubMed Web of Science ®Google Scholar
• Shi W, Wang YM, Li LS, et al. Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a six-month randomised study. Clin Drug Investig. 2004;24(2):89–101. doi: 10.2165/00044011-200424020-00004
   PubMed Web of Science ®Google Scholar
• Bobek D, Banić Stipetić A, Franić M, et al. Use of non-steroidal anti-inflammatory drugs in patients with advanced active rheumatoid arthritis. Acta Clin Croat. 2022;61:588–598. doi: 10.20471/acc.2022.61.04.04
   PubMed Web of Science ®Google Scholar
• Svanström H, Lund M, Melbye M. Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2018;27:885–893. doi: 10.1002/pds.4555
   PubMed Web of Science ®Google Scholar
• Bergstra SA, Sepriano A, Kerschbaumer A, et al. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):81–94. doi: 10.1136/ard-2022-223358
   PubMed Web of Science ®Google Scholar
• Morand EF. Effects of glucocorticoids on inflammation and arthritis. Curr Opin Rheumatol. 2007;19(3):302–7. doi: 10.1097/BOR.0b013e32805e87d0
   PubMed Web of Science ®Google Scholar
• Pelechas E, Drosos AA. State-of-the-art glucocorticoid-targeted drug therapies for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2022;23(6):703–711. doi: 10.1080/14656566.2022.2049238
   PubMed Web of Science ®Google Scholar
• Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;1998:CD001158. doi: 10.1002/14651858.CD001158
   PubMedGoogle Scholar
• Hoes JN, Jacobs JW, Buttgereit F. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol. 2010;6:693–702. doi: 10.1038/nrrheum.2010.179
   PubMed Web of Science ®Google Scholar
• Fox RI Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 Suppl 1):82–91. doi: 10.1016/S0049-0172(10)80012-5
   PubMed Web of Science ®Google Scholar
• Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–166. doi: 10.1038/s41584-020-0372-x
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY. American Academy of Ophthalmology. Recommendations on screening for chloroquine and Hydroxychloroquine retinopathy (2016 revision). Ophthalmol. 2016;123:1386–1394. doi: 10.1016/j.ophtha.2016.01.058
   PubMed Web of Science ®Google Scholar
• Jorge A, Ung C, Young LH. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. Nat Rev Rheumatol. 2018;14:693–703. doi: 10.1038/s41584-018-0111-8
   PubMed Web of Science ®Google Scholar
• Nazir AM, Koganti B, Gupta K, et al. Evaluating the use of Hydroxychloroquine in treating patients with rheumatoid arthritis. Cureus. 2021;13:e19308. doi: 10.7759/cureus.19308
   PubMed Web of Science ®Google Scholar
• Bergstra SA, Allaart CF, Ramiro S, et al. Sex-associated treatment differences and their outcomes in rheumatoid arthritis: results from the METEOR register. J Rheumatol. 2018;45(10):1361–1366. doi: 10.3899/jrheum.171176
   PubMed Web of Science ®Google Scholar
• Nell VP, Machold KP, Eberl G. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906–914. doi: 10.1093/rheumatology/keh199
   PubMed Web of Science ®Google Scholar
• van Aken J, Lard LR, le Cessie S. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. 2004;63:274–279. doi: 10.1136/ard.2003.010298
   PubMed Web of Science ®Google Scholar
• Wabe N, Wojciechowski J, Wechalekar MD, et al. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy. Int J Of Rheum Dis. 2017;20(10):1447–1456. doi: 10.1111/1756-185X.13184
   PubMed Web of Science ®Google Scholar
• Suarez-Almazor ME, Belseck E, Shea B. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;1998:CD000958. doi: 10.1002/14651858.CD000958
   PubMedGoogle Scholar
• Smedegård G, Björk J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol. 1995;34 Suppl 2:7–15. doi: 10.1093/rheumatology/XXXIV.suppl_2.7
   PubMedGoogle Scholar
• Rains CP, Noble S, Faulds D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs. 1995;50:137–156. Erratum in: Drugs 1995;50(4). doi: 10.2165/00003495-199550010-00009
   PubMed Web of Science ®Google Scholar
• Mundo A, Pedone V, Lamanna G, et al. La sulfasalazina: effetti collaterali e durata della terapia in pazienti affetti da artrite reumatoide [Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis]. Clin Ter. 1997;148:7–13.
   PubMedGoogle Scholar
• Wilkieson CA, Madhok R, Hunter JA, et al. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages. Q J Med. 1993;86(8):501–5. doi: 10.1093/qjmed/86.8.501
   PubMedGoogle Scholar
• Boyd O, Gibbs AR, Smith AP. Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis. Br J Rheumatol. 1990;29(3):222–4. doi: 10.1093/rheumatology/29.3.222
   PubMedGoogle Scholar
• Farr M, Kitas GD, Tunn EJ, et al. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. Br J Rheumatol. 1991;30(6):413–7. doi: 10.1093/rheumatology/30.6.413
   PubMedGoogle Scholar
• Khattak FH, Morris IM, Mattingly PC. Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. Br J Rheumatol. 1996;35(1):104. doi: 10.1093/rheumatology/35.1.104
   PubMedGoogle Scholar
• Amos RS, Pullar T, Bax DE, et al. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. Br Med J (Clin Res Ed). 1986;293(6544):420–3. doi: 10.1136/bmj.293.6544.420
   PubMedGoogle Scholar
• Hannonen P, Möttönen T, Hakola M, et al. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum. 1993;36(11):1501–9. doi: 10.1002/art.1780361104
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990;33:1449–1461. doi: 10.1002/art.1780331001
   PubMed Web of Science ®Google Scholar
• Pullar T, Hunter JA, Capell HA. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis. 1987;46(5):398–402. doi: 10.1136/ard.46.5.398
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van Riel PL, Nuver-Zwart IH. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036–1038. doi: 10.1016/S0140-6736(89)92442-2
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van Riel PL, Nuver-Zwart IH. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up. Lancet. 1990;335:539. doi: 10.1016/0140-6736(90)90771-V
   PubMed Web of Science ®Google Scholar
• Verschueren P, De Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74(1):27–34. doi: 10.1136/annrheumdis-2014-205489
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Pizzorni C. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60:729–735. doi: 10.1136/ard.60.8.729
   PubMed Web of Science ®Google Scholar
• Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016;12(12):731–742. doi: 10.1038/nrrheum.2016.175
   PubMed Web of Science ®Google Scholar
• Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–9. doi: 10.1136/ard.2008.092668
   PubMed Web of Science ®Google Scholar
• MC-MTX.6/RH Study Group, Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73–81.
   PubMed Web of Science ®Google Scholar
• Hanoodi M, Mittal M Methotrexate. [ Updated 2023 Aug 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556114/
   Google Scholar
• Verschueren P, De Cock D, Corluy L, et al. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann Rheum Dis. 2017;76:511–520. doi: 10.1136/annrheumdis-2016-209212
   PubMed Web of Science ®Google Scholar
• Hetland ML, Haavardsholm EA, Rudin A, et al. NORD-STAR study group. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ. 2020;371:m4328. doi: 10.1136/bmj.m4328
   PubMedGoogle Scholar
• Padda IS, Goyal A Leflunomide. [ Updated 2023 Jun 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557799/
   Google Scholar
• Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2000;59:841–849. doi: 10.1136/ard.59.11.841
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis. Clin Ther. 1999;21(11):1837–52. discussion 1821. doi: 10.1016/S0149-2918(00)86732-6
   PubMed Web of Science ®Google Scholar
• Keen HI, Conaghan PG, Tett SE. Safety evaluation of leflunomide in rheumatoid arthritis. Expert Opin Drug Saf. 2013;12(4):581–8. doi: 10.1517/14740338.2013.798299
   PubMed Web of Science ®Google Scholar
• Bao C, Chen S, Gu Y, et al. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Chin Med J (Engl). 2003;116:1228–1234.
   PubMed Web of Science ®Google Scholar
• Maddison P, Kiely P, Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford). 2005;44(3):280–6. doi: 10.1093/rheumatology/keh500
   PubMed Web of Science ®Google Scholar
• Rozman B Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide investigators’ group. J Rheumatol Suppl. 1998;53:27–32.
   PubMedGoogle Scholar
• Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2003;30:1182–1190.
   PubMed Web of Science ®Google Scholar
• Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis.Leflunomide rheumatoid arthritis investigators group. Arthritis Rheum. 2000;43(3):495–505. doi: 10.1002/1529-0131(200003)43:3<495:AID-ANR4>3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial.European Leflunomide study group. Lancet. 1999;353(9149):259–66. doi: 10.1016/S0140-6736(98)09403-3
   PubMed Web of Science ®Google Scholar
• Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis trial Investigator group. Arthritis Rheum. 2001;44(9):1984–92. doi: 10.1002/1529-0131(200109)44:9<1984:AID-ART346>3.0.CO;2-B
   PubMedGoogle Scholar
• Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA; PRECIS study group, all physicians belong to division of internal Medicine. Hospital central sur de Pemex. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin (Engl Ed). 2019;15:133–139 3 10.1016/j.reuma.2017.07.020
   PubMed Web of Science ®Google Scholar
• Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350(9074):309–18. doi: 10.1016/S0140-6736(97)01300-7
   PubMed Web of Science ®Google Scholar
• Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46:347–356. doi: 10.1002/art.10083
   PubMed Web of Science ®Google Scholar
• van Tuyl LH, Boers M, Lems WF, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010;69:807–812.
   PubMed Web of Science ®Google Scholar
• Poppelaars PBM, van Tuyl LHD, Boers M. Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. Ann Rheum Dis. 2019;78(5):586–589. doi: 10.1136/annrheumdis-2018-214618
   PubMed Web of Science ®Google Scholar
• Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 1999;353(9164):1568–73. doi: 10.1016/S0140-6736(98)08513-4
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381–90. doi: 10.1002/art.21405
   PubMed Web of Science ®Google Scholar
• Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008;58(5):1310–7. doi: 10.1002/art.23449
   PubMedGoogle Scholar
• Register KA, Cannella AC, Mikuls TR, et al. Leflunomide, Sulfasalazine and Hydroxychloroquine for Rheumatoid Arthritis: Efficacious but Poorly Tolerated [abstract]. Arthritis & Rheumat. 2016; 68 (suppl 10)
   Google Scholar
• Chen F, Wang Y, Wang L. Combination of methotrexate and Leflunomide is efficient and safe for 60 patients with rheumatoid arthritis. Comput Math Methods Med. 2022;2022:1–6. doi: 10.1155/2022/6829358
   Web of Science ®Google Scholar
• Kremer J, Genovese M, Cannon GW, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2004;31:1521–1531.
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clin Rheumatol. 2020;39(4):1363–1368. doi: 10.1007/s10067-020-05001-x
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Voulgari PV. Rheumatoid arthritis treatment. A back to the drawing board project or high expectations for low unmet needs? J Clin Med. 2019;8(8):1237. doi: 10.3390/jcm8081237
   PubMed Web of Science ®Google Scholar
• Drosos AA, Pelechas E, Kaltsonoudis E, et al. Therapeutic options and cost-effectiveness for rheumatoid arthritis treatment. Curr Rheumatol Rep. 2020;22:44. 10.1007/s11926-020-00921-8
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Geborek P, Forslind K, et al. Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group swefot trial. Lancet. 2012;379:1712–1720. doi: 10.1016/S0140-6736(12)60027-0
   PubMed Web of Science ®Google Scholar
• O’Dell JR, Mikuls TR, Taylor TH, et al. CSP 551 RACAT investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–18. doi: 10.1056/NEJMoa1303006
   PubMed Web of Science ®Google Scholar
• Moreland LW, O’Dell JR, Paulus HE, et al. TEAR investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 2012;64(9):2824–35. doi: 10.1002/art.34498
   PubMed Web of Science ®Google Scholar
• Bathon JM, McMahon DJ. Making rational treatment decisions in rheumatoid arthritis when methotrexate fails. N Engl J Med. 2013;369(4):384–5. doi: 10.1056/NEJMe1306381
   PubMed Web of Science ®Google Scholar